Exercise and cannabinoid receptors: new hope for Parkinson's disease

This review examines how G protein-coupled receptors (GPCRs) play a central role in Parkinson's disease pathology and how exercise may work as a therapeutic intervention through GPCR signaling pathways. Parkinson's disease involves the progressive loss of dopaminergic neurons and widespread neural dysfunction, resulting in both motor symptoms like tremor and rigidity, and non-motor symptoms like depression and sleep disorders. The research highlights that cannabinoid receptors are one of several key GPCR superfamilies involved in core pathological processes including alpha-synuclein aggregation, neuroinflammation, and oxidative stress—all hallmarks of Parkinson's progression.

The paper emphasizes that exercise is an underutilized non-pharmacological therapy that shows promise in ameliorating both motor and non-motor symptoms, likely through its effects on GPCR-mediated signaling. Cannabinoid receptors, alongside dopamine, serotonin, and adenosine receptors, modulate critical disease mechanisms that could be targeted therapeutically. This integrated approach suggests that understanding how exercise influences GPCR activity—particularly through cannabinoid signaling—could lead to more effective personalized treatment strategies combining exercise regimens with GPCR-targeted therapies.

For cannabis researchers and patients interested in cannabinoid therapeutics, this work provides important context: cannabinoid receptors are recognized as legitimate therapeutic targets in neurodegenerative disease, functioning alongside conventional dopaminergic treatments. The research establishes a scientific foundation for investigating how CBD or other cannabinoid-based therapies might synergize with exercise-based interventions to address Parkinson's multisystem pathology, rather than targeting symptoms in isolation.